stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/company.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Stemline Therapeutics, Inc. Is a clinical stage biopharmaceutical company developing novel therapeutics that target cancer stem cells (CSCs) and tumor bulk. Stemline is developing two clinical stage product candidates, SL-401 and SL-701, and a pipeline of preclinical candidates that includes SL-801. Is a novel oral small molecule reversible inhibitor of Exportin-1 (XPO1). SL-801 has demonstrated broad. Stemline's preclini...
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/clinical-trials.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Acute Myeloid Leukemia (AML), Relapsed/Refractory. AML, in First Complete Remission (CR) with Minimal Residual Disease (MRD. AML, in 1st CR,. Advanced, High Risk Myeloproliferative Neoplasms (MPN). Relapsed/Refractory Multiple Myeloma in Combination with Pomalidomide. Adult Glioblastoma Multiforme (GBM), in First Recurrence. SL-801 Advanced Solid Tumors.
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/platform.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Stemline Therapeutics has developed a Discovery Platform called StemScreen. To identify novel compounds that target and kill CSCs. Is a 3-step platform which involves:. CSC isolation and target identification. Screen which identifies compound classes that interact with CSC targets. Battery of anti-CSC functional assays that test compounds for activity against CSCs both.
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/newsArticleDetails.asp?id=117
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Stemline Therapeutics Reports Second Quarter 2015 Financial Results. NEW YORK, August 10, 2015 (GLOBE NEWSWIRE) - Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel oncology drugs that primarily target cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended June 30, 2015. Second Quarter 2015 Financial Results Review. Research and d...
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/csc.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Researchers have identified Cancer Stem Cells (CSCs). As the highly malignant "seeds" of tumors, typically comprising 1-5% of the tumor, that give rise to the majority (95-99%) of other tumor cells known as the "tumor bulk".
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/scientific-presentations.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2016. Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing. ASCO 2016. SL-401, A Novel Targeted Therapy Directed To The Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic...
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/newsEvents.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Stemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401. Stemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference. Stemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress. Stemline Therapeutics’ SL-401 Phase 2 BPDCN Data Selected for Oral Presentations at the Upcoming ASCO and EHA Meetings.
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/organization.asp
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Ivan Bergstein, M.D. Chief Executive Officer and President. Vice President of Finance and Chief Accounting Officer.
stemline.com
Stemline Therapeutics, Inc.
http://www.stemline.com/newsArticleDetails.asp?id=116
Targeting cancer at its root. Developing novel drugs that attack Cancer Stem Cells. Stemline Therapeutics to Present at the 2015 Wedbush PacGrow Healthcare Conference. Stemline Therapeutics, Inc. New York, NY 10022.
SOCIAL ENGAGEMENT